This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
Cell reports · 2015 · senior author
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Arteriosclerosis, thrombosis, and vascular biology · 2015 · senior author
The anti-hypercholesterolemic effect of low p53 expression protects vascular endothelial function in mice.
PloS one · 2014
Latest funding
- $929,476
Preclinical development of highly potent and orally bioavailable PCSK9 inhibitors for patients at high cardiovascular risk
CIHR · 2024 · Nominated PI
- $100,000
Preclinical development of highly potent and orally bioavailable PCSK9 inhibitors for patients at high cardiovascular risk
CIHR · 2023 · Nominated PI
- $524,521
Function of PCSK9 in LDLR and CD36 degradation: LDL cholesterol regulation and beyond.
CIHR · 2013 · Nominated PI
6 publications.
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, Mayer G
The anti-hypercholesterolemic effect of low p53 expression protects vascular endothelial function in mice.
Leblond F, Poirier S, Yu C, Duquette N, Mayer G, Thorin E
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, Asselin MC, Day R, Duclos FJ, Witmer M, Parker R, Prat A, Seidah NG
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG
The activation and physiological functions of the proprotein convertases.
Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A
Preclinical development of highly potent and orally bioavailable PCSK9 inhibitors for patients at high cardiovascular risk
Principal investigators: Mayer, Gaétan
Keywords: Atherosclerosis; Cardiovascular Diseases; Drug Development; Hypercholesterolemia; Lipid Metabolism; Lipoprotein Receptor/Ldlr; Proprotein Convertase Subtilisin Kexin 9 (Pcsk9); Small Molecule Drugs
Preclinical development of highly potent and orally bioavailable PCSK9 inhibitors for patients at high cardiovascular risk
Principal investigators: Mayer, Gaétan
Keywords: Atherosclerosis; Cardiovascular Diseases; Drug Development; Hypercholesterolemia; Lipid Metabolism; Lipoprotein Receptor/Ldlr; Proprotein Convertase Subtilisin Kexin 9 (Pcsk9); Small Molecule Drugs
Function of PCSK9 in LDLR and CD36 degradation: LDL cholesterol regulation and beyond.
Principal investigators: Mayer, Gaétan
Keywords: Adipose Tissue; Atherosclerosis; Cardiovascular Diseases; Cd36; Endocytosis; Hypercholesterolemia; Lipoproteins/Fatty Acids; Liver; Low-Density Lipoprotein Receptor (Ldlr); Lysosomes; Molecular And Cellular Biology; Proprotein Convertase Subtilisin/Kexin Type-9 (Pcsk9); Protein Trafficking
The PCSK9-induced degradation of cell surface receptors: LDL cholesterol regulation and beyond.
Principal investigators: Mayer, Gaétan
Keywords: Atherosclerosis; Biochemistry; Cardiovascular Diseases; Endocytosis; Hypercholesterolemia; Lipoproteins; Low-Density Lipoprotein Receptor (Ldlr); Lysosomes; Metabolic Syndrome; Molecular And Cellular Biology; Proprotein Convertase Subtilisin/Kexin Type-9 (Pcsk9); Protein Trafficking
Molecular characterization and inhibition of the PCSK9-assisted low-density lipoprotein receptor degradation pathway.
Principal investigators: Mayer, Gaétan
Keywords: Atherosclerosis; Biochemistry; Cardiovascular Diseases; Cell Biology; Cholesterol-Lowering Drug; Endocytosis; Hypercholesterolemia; Low-Density Lipoprotein Receptor (Ldlr); Lysosomes; Molecular Biology; Proprotein Convertase Subtilisin/Kexin Type-9 (Pcsk9); Protein Trafficking
Molecular characterization and inhibition of the PCSK9-assisted low-density lipoprotein receptor degradation pathway.
Principal investigators: Mayer, Gaétan
Keywords: Atherosclerosis; Biochemistry/Microscopy; Cardiovascular Diseases; Cell Biology; Cholesterol-Lowering Drug; Endocytosis; Hypercholesterolemia; Ldlr; Low-Density Lipoprotein Receptor; Lysosomes; Molecular Biology; Pcsk9; Proprotein Convertase Subtilisin/Kexin Type-9; Protein Trafficking
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Eric Thorin and Eric Thorin: 81 shared papers
- Eric Thorin and Christine Des Rosiers: 5 shared papers
- Christine Des Rosiers and Eric Thorin: 5 shared papers
- Gaétan Mayer and Annik Prat: 3 shared papers
- Gaétan Mayer and Eric Thorin: 1 shared paper
- Gaétan Mayer and Christine Des Rosiers: 1 shared paper
- Gaétan Mayer and Eric Thorin: 1 shared paper
- Medicine
- Biochemical Neuroendocrinology
- Surgery
- Other
Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.